Author: Willem van Lawick

– Results from the single dose 1-year follow up consistent with prior Phase II study
– Data supports already submitted marketing authorization application

Amsterdam-Duivendrecht, The Netherlands, January 31, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell therapy products aiming to make bone marrow transplantations safer and more effective for patients, today announces that the last patient in the Phase II CR-AIR-008 (‘008’) trial has received a single dose of ATIR101™.
This exploratory Phase II trial (clinicaltrials.gov identifier: NCT02500550) was designed to evaluate the safety and efficacy of two doses of ATIR101™ in patients with a hematologic malignancy who received a hematopoietic stem cell transplantation from a haploidentical (half-matched) donor.
A total of 15 patients were recruited into the trial. Six of these patients received two doses of ATIR101™ before the independent data monitoring committee (IDMC) recommended that the trial should continue treating patients with one dose of ATIR101™ (announced on December 21, 2016). The remaining nine patients on the trial have now been treated with a single dose of ATIR101™. Of these nine patients, five patients are 1-year post treatment and results are consistent with the previously conducted 23-patient CR-AIR-007 single dose Phase II trial. (more…)

Amsterdam-Duivendrecht, The Netherlands, January 16, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell therapy products to make bone marrow transplantations safer and more effective for patients, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory Board will nominate Subhanu Saxena to be appointed as a new member of the Supervisory Board.
Subhanu Saxena is currently a Regional Director with The Bill & Melinda Gates Foundation as well as partner New Rhein Healthcare and Senior Advisor to Bain Capital. He was, until recently, the Managing Director and Global Chief Executive Officer of Cipla, a publicly listed, leading Indian pharmaceutical and biotech company with global operations and around 25,000 employees. During Mr. Saxena’s leadership Cipla was transformed into a more international and agile company. Prior to joining Cipla, Mr. Saxena was Head of Global Product Strategy and Commercialization and member of the Executive Committee at Novartis. Before that, Mr. Saxena was CEO of Novartis UK and held various leadership roles in business development. Prior to joining the pharma industry Mr. Saxena worked with leading global companies including Citicorp, the Boston Consulting Group and PepsiCo across markets in Europe, North America, Africa and Asia. Mr. Saxena holds a Graduate degree in Engineering from Oxford University and an MBA from INSEAD, France. (more…)

Amsterdam-Duivendrecht, The Netherlands, December 6, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell therapy products to make bone marrow transplantations safer and more effective for patients, today announces that it has entered into an agreement to lease an existing commercial manufacturing facility, which includes process development and quality control laboratories, as well as space for the Kiadis Pharma headquarters in Amsterdam, The Netherlands. The facility is located at Paasheuvelweg 25A in Amsterdam, The Netherlands.
The in-house manufacturing capability will allow the Company to enhance flexibility and expand capacity, and will not affect the ongoing contract manufacturing collaborations.
Arthur Lahr, CEO of Kiadis Pharma, commented: “As we continue to prepare for European launch in 2019, this provides Kiadis with a unique opportunity to obtain access to a recently established state-of-the-art commercial manufacturing facility in Amsterdam without spending capital and time on a construction project. Also, we can now locate all our activities at a single site.”
(more…)

Amsterdam-Duivendrecht, The Netherlands, December 4, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell-therapy products to make bone marrow transplantations safer and more effective for patients, today announces that the first patient has been enrolled in the HATCY Phase 3 clinical trial for ATIR101™.
The multinational trial will evaluate the safety and efficacy of ATIR101™ as an adjunctive treatment to blood stem cell transplantation from a half-matched (haploidentical) family donor compared to post-transplant cyclophosphamide (PTCy or ‘Baltimore’ protocol) in adult patients with blood cancer.
Andrew Sandler, Chief Medical Officer of Kiadis Pharma, commented: “We are pleased that the first patient has been enrolled in the Phase 3 trial for our innovative cell-therapy product ATIR101™. Although the ‘Baltimore’ protocol has made haploidentical transplants feasible, a huge unmet need remains due to high relapse rates and occurrence of graft versus host disease.”
Arthur Lahr, Chief Executive Officer of Kiadis Pharma, commented: “The start of this large multinational Phase 3 clinical trial marks another important step in the development of Kiadis. We aim to submit the results from this Phase 3 trial to the US FDA, while we continue to progress the European filing submitted earlier this year to EMA based on our Phase 2 data.”
(more…)

Amsterdam-Duivendrecht, The Netherlands, October 10, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that it has raised gross proceeds of €18 million through an undocumented private placement of 2.25 million new shares to institutional investors via an accelerated bookbuilding process as announced on October 9, 2017 (the “Placing”). The Placing was completed at a subscription price of €8.00 per share and represented 15.0% of the issued share capital of the Company prior to the transaction.

The new ordinary shares will rank pari passu in all respects with the currently outstanding shares of the company and are expected to be listed and traded on Euronext Amsterdam and Brussels on October 12, 2017. Following the Placing, the issued share capital of the Company will be 17,287,397.
The proceeds from the Placing, combined with €2.3 million received by Kiadis Pharma from the exercise of warrants placed pursuant to the Company’s private placement of June 13, 2017, will allow the company to draw down an additional €5 million of debt financing from Kreos Capital as announced on August 17, 2017. (more…)